U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06824064) titled 'Evaluation of RBS2418 in Patients with Advanced, Metastatic, and Progressive Colorectal Cancer' on Jan. 30.
Brief Summary: RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation. The hypothesis is that RBS2418 versus placebo will be generally safe, well-tolerated, immunogenic, and will lead to anti-tumor responses...